Knight Therapeutics Inc
TSX:GUD
Knight Therapeutics Inc
Operating Income
Knight Therapeutics Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Operating Income
CA$7.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurora Cannabis Inc
TSX:ACB
|
Operating Income
-CA$160.4m
|
CAGR 3-Years
28%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-54%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Operating Income
-CA$33.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Operating Income
-$59.5m
|
CAGR 3-Years
33%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
C
|
Curaleaf Holdings Inc
CNSX:CURA
|
Operating Income
$12.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Operating Income
$7.8m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
Knight Therapeutics Inc
Glance View
Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.
See Also
What is Knight Therapeutics Inc's Operating Income?
Operating Income
7.4m
CAD
Based on the financial report for Dec 31, 2024, Knight Therapeutics Inc's Operating Income amounts to 7.4m CAD.
What is Knight Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 1Y
16%
Over the last year, the Operating Income growth was 16%.
You don't have any saved screeners yet